OncoMatch/Clinical Trials/NCT07627334
Personalized Targeted Glioblastoma Therapies by ex Vivo Drug Screening: Advanced Brain Tumor TheRApy Clinical Trial In Patients Scheduled for shOrt Course radiatioN
Is NCT07627334 recruiting? Yes, currently enrolling (Jul 2026). This NA trial studies non-drug interventions for glioblastoma (gbm).
Patients will receive in addition to standard histology analysis also the PDC- based drug screening.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Biomarker criteria
Required: IDH1 wild-type
IDH-wildtype
Required: MGMT unmethylated promotor
Unmethylated MGMT promotor per local assessment
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07627334 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require IDH1?
Yes, IDH1 wild-type is a required biomarker for enrollment.
Does this trial require MGMT?
Yes, MGMT unmethylated promotor is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages